This research report is a separate document:
招商证券国际：中国生物科技服务22年一季度收入增长强劲，夯实公司在港检测龙头地位
China Merchants Securities International: China Biotech Services saw strong revenue growth in the first quarter of '22, consolidating the company's leading position in testing in Hong Kong
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.